February

  • Partnerships with pharmaceutical companies Fosun and Ipsen added

March

  • Raised £87m (gross) on LSE
  • Positive Ph2 COPD data from Verona
  • Amplyx receives QIDP (Qualified Infectious Disease Product) for APX001 from the FDA

May

  • Iterum completes NASDAQ IPO
  • AtoxBio initiates Phase 2 clinical trial of Acute Kidney Injury (AKI)

June

  • Autolus completes $150m NASDAQ IPO

August

  • Arix announces first VIPE investment, in Pharmaxis
  • Artios completes £65m Series B funding – Arix becomes the largest shareholder in the company
  • Harpoon initiates HPN424 Phase 1 Prostate Cancer Trial
  • Iterum initiates SURE 1 Phase 3 trial in uncomplicated UTI
  • Verona initiates a Phase 2 trial evaluating Nebulized RPL554 as an add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

September

  • Art Pappas appointed as NED
  • Iterum initiates SURE 2 and SURE 3 Phase 3 clinical trials of Complicated Urinary Tract Infections and Complicated Intra-abdominal Infections

October

  • Arix co-leads $58m Series A funding for VelosBio
  • Pharmaxis releases positive Phase 1 data for first LOXL2 compound
  • LogicBio completes $80m NASDAQ IPO
  • Aura announces positive Phase 1b/2 data from AU-011, its lead product candidate for the primary treatment of choroidal melanoma

November

  • Harpoon completes $70m Series C fundraise
  • Pharmaxis releases positive Phase 1 clinical trial results for second LOXL2 inhibitor Compound
  • Amplyx doses first patient in Phase 2 APX001 trial in patients with Candida Infection

December

  • Autolus:presents positive initial data from its AUTO3 programme at ASH, which includes ongoing Phase 1/2 trials in pediatric Acute Lymphoblastic Leukaemia (AMELIA trial) and Diffuse B-cell Lymphoma (ALEXANDER trial)
    • positive preclinical data for AUTO5 programme, targeting TRBC2-positive peripheral T-cell Lymphoma
    • first patient dosed in Phase 1/2 trial of AUTO4 in TRBC1-positive peripheral T-cell lymphoma
  • Arix expands investment team with the addition of Dr Christian Schetter as Entrepreneur-in-Residence
  • Harpoon announces proposed NASDAQ IPO